Anika Therapeutics Inc., of Woburn, Mass., added William Knight as chief financial officer.
Applied Molecular Evolution Inc., of San Diego, appointed William Respess vice president and general counsel.
BioEnterprise Corp., of Cleveland, named Baiju Shah vice president.
Biogen Inc., of Cambridge, Mass., appointed Christine Carberry vice president, program and alliance management.
BioMarin Pharmaceuticals Inc., of Novato, Calif., established a science advisory board consisting of Richard Beliveau, Jeffrey Borer, Robert Langer, William Mobley, Steven Peikin, David Rimoin, James Swartz and John Urquhart.
BioXell SpA, of Milan, Italy, appointed Bernd Seizinger to its board.
Celera Genomics Group, of Rockville, Md., appointed Robert Booth senior vice president of research and development, effective Aug. 5.
Comprehensive NeuroScience Inc., of White Plains, N.Y., appointed James Ballenger senior vice president for scientific development and director of drug development; J.B. Goss senior vice president, corporate director for professional marketing and sales; and Regina Reale vice president of strategic development.
CXR Biosciences Ltd., of Dundee, UK, appointed Tom Shepherd chief executive.
Elixir Pharmaceuticals Inc., of Cambridge, Mass., appointed Alan Watson chief business officer and executive vice president.
Epicyte Pharmaceutical Inc., of San Diego, named Bruce Davis vice president of manufacturing and Catherine Lee director of formulation development.
Favrille Inc., of San Diego, appointed Richard Murawski senior vice president of operations.
FeRx Inc., of San Diego, added Gilad Gordon as vice president of medical affairs.
Genaissance Pharmaceuticals Inc., of New Haven, Conn., named Kevin Rakin chief operating officer and promoted Joseph Keyes to vice president and chief financial officer.
Genzyme General, of Cambridge, Mass., appointed John Butler senior vice president and general manager of its renal business unit and Edmund Sybertz senior vice president and general manager of its GelTex Pharmaceuticals unit.
Guava Technologies Inc., of Hayward, Calif., added John Reed to its scientific advisory board.
Immtech International Inc., of Vernon Hills, Ill., added Frederick Wackerle to its board.
Immuno-Designed Molecules SA, of Paris, added Nadine Sciacca as communications director.
InterMune Inc., of Brisbane, Calif., added William Ringo and William Halter to its board.
ISTA Pharmaceuticals Inc., of Irvine, Calif., added Thomas Mitro as vice president, sales and marketing.
Lipid Sciences Inc., of Pleasanton, Calif., elected Lewis Meyer to its board.
Neurion Pharmaceuticals Inc., of Los Angeles, appointed Steven Hyman, Kendall Houk and Robert Grubbs to its scientific advisory board.
Novoste Corp., of Norcross, Ga., promoted Andrew Green to vice president, regulatory affairs.
Ontogen Corp., of Carlsbad, Calif., appointed Richard Soll vice president of chemistry and promoted Michael Newman to vice president of biology.
OraPharma Inc., of Warminster, Pa., appointed David Wright to its board.
Oxagen Ltd., of Abingdon, UK, added Mark Payton as CEO designate and he also will function as chief scientific officer. Trevor Nicholls, the current CEO, is expected to leave this year. Mark Edwards will take the chief technology officer role in the company.